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ABSTRACT
Background: Periodontal disease status in diabetic patients has been shown to correlate
positively with Plasma HbA1c. But its association with serum Fructosamine remains unclear,
more so, when the severity is expressed as a continuous quantitative variable.
Aim: To analyze the relationship between HbA1c, Fructosamine (FA) and periodontal
disease severity expressed as Attachment Loss Surface Area (ALSA) and Periodontal
Inflamed Surface Area (PISA) in patients with and without Type 2 Diabetes Mellitus.
Materials and Methods: ALSA and PISA were calculated in 60 type 2 diabetics and 40
non-diabetics with generalized chronic periodontitis and their HbA1c and FA levels were
assessed using an enzymatic assay. Pearson correlation was used to analyze the association
between these variables. Multiple linear regression (backward) was performed to analyze the
predictability of ALSA and PISA from these glycemic markers, age, gender, duration of
diabetes and Plaque index (Pl I).
Results: The glycemic markers showed a very high inter-correlation in the diabetics and a
moderate correlation in the non-diabetic group. They exhibited a good to moderate
correlation with ALSA and PISA in the diabetics and none significant in the non-diabetics.
Multiple regression analysis revealed that the most significant predictors for ALSA in the
diabetic group were the glycemic control, Pl I and age, while those for PISA were glycemic
control and Pl I.  The only significant predictor of PISA in the non-diabetics was Pl I and
none was significantly predictive of ALSA in this group.
Conclusions: Fructosamine is a valid alternative to HbA1c for the evaluation of glycemic
status in generalized chronic periodontitis patients with Type 2 Diabetes.  Poor glycemic
control has a significant and direct contribution towards ALSA and PISA in these patients.
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1INTRODUCTION
2Periodontal disease. The Sixth Complication of Diabetes Mellitus
- Loe H (1993)1
Diabetes mellitus is the second most common metabolic disorder in human with
Type 2 diabetes (formerly Non Insulin Dependent Diabetes Mellitus) accounting for 90-
95% of all the cases.2 Chronic periodontitis is defined as “an infectious disease resulting
in inflammation within the supporting tissues of the teeth, progressive attachment loss
and bone loss.”3 Though there is an essential bacterial etiology, the interaction of the
micro-organism with the host determines the course and extent of the resulting disease.
Several factors like systemic disorders and conditions, environmental, physical and
psychosocial factors have the potential to alter the periodontal tissues and the host
immune response, resulting in more severe periodontal disease expression.4
Diabetes is a clear risk factor for periodontitis.5 Hence the evaluation of the
glycemic status of a patient is mandatory prior to any periodontal intervention. The
traditional methods like random blood glucose, fasting blood glucose and two hour post-
prandial glucose offer only the “Snapshot” information, i.e. glucose concentration at that
point of time, and are of limited value from a periodontal point of view.4 HbA1c has been
considered the gold standard for the evaluation of the long term glycemic status in a
diabetic patient.6,7 Fructosamine assay, the alternative to HbA1c has shown good
correlation with HbA1c8,9 with additional advantages of being economical and simple in
laboratory procedure.9 Further, it serves as a valuable alternative in conditions where
HbA1c is likely to be misleading such as hemoglobinopathies or anemia.8
The severity of the periodontal disease is often represented as non-continuous
variables (mild, moderate, severe etc) which in the truest sense do not quantify the
3amount of affected periodontal tissue. Using continuous variables such as mean probing
pocket depth or mean clinical attachment level has partly addressed this issue, but the
primary problem still remains.10,11 A classification that quantified the total surface area of
attachment loss, later referred to as Attachment Loss Surface Area (ALSA) was given by
Hujoel et al.12 Another important parameter, the Periodontal Inflamed surface Area
(PISA) which quantifies the systemic burden of the periodontal disease in a patient was
proposed by Nesse et al.10
Though the literature is replete with the studies on the association between
periodontal disease status and Plasma HbA1c, there is a dearth of literature regarding its
relationship with serum fructosamine level. The paucity is even more pronounced for the
comparative evaluation of the association between these two measures of Glycemic
control and the periodontal disease severity quantified in terms of ALSA or PISA.
Therefore, it was deemed appropriate to conduct a study to comparatively analyze the
relationship between plasma Glycated hemoglobin and serum Fructosamine levels and
the severity of Generalized Chronic Periodontitis expressed in terms of ALSA and PISA
in patients with and without Type 2 Diabetes mellitus.
4AIM AND OBJECTIVES
51. To evaluate the association, if any, between plasma Glycated Hemoglobin level
and periodontal disease severity expressed as Attachment Loss Surface Area
(ALSA) and Periodontal Inflamed Surface Area (PISA), in generalized chronic
periodontitis patients with and without Type 2 Diabetes mellitus.
2. To assess the association, if any, between serum Fructosamine level and
periodontal disease severity expressed as ALSA and PISA, in generalized
chronic periodontitis patients with and without Type 2 Diabetes mellitus.
3. To evaluate the predictability of the periodontal disease severity from these two
measures of glycemic control in generalized chronic periodontitis patients with
and without Type 2 Diabetes mellitus.
6REVIEW OF LITERATURE
7Historical perspective of HbA1c and Fructosamine
HbA1c
Hemoglobin A1c was first separated from other forms of hemoglobin by
Huisman andMeyering in 1958 13 using a chromatographic column.
HBA1c was characterized as a glycoprotein by Bookchin and Gallop in 1968.14
Its increase in diabetes was first described in 1969 by Rahbar S et al.15 An
unusual hemoglobin was found in patients with diabetes mellitus which resembled those
of hemoglobin A1c prepared from normal subjects. They suggested the possibility that an
amino sugar is bound to hemoglobin A1c in diabetic patients.
The reactions leading to the formation of HbA1c were characterized by Bunn
HF and his co-workers in 1975. 16 They proposed that in the red cell, glucose binds to the
α-amino position of hemoglobin β-chains (valine) in an aldimine (Schiff base) linkage.
This aldimine can then partially rearrange in a reversible manner to form a ketoamine
linkage which is stable to acid hydrolysis. This Amadori-type of rearrangement accounts
for the formation of mannose, the C-2 epimer of glucose, as well as the inability to
demonstrate 3H---Na BH4 reduction at the C-1 position.
H F Bunn et al 17 stated that HbA1c is formed by the condensation of glucose
with the N-terminal amino groups of the beta-chains of Hb A. The specific activity of Hb
A1c was found to be significantly lower than that of Hb A, suggesting that the formation
of Hb A1c is a posttranslational modification. Its specific activity rose slowly, reaching
that of Hb A by about day 60, indicating that Hb A1c is formed during the 120-day life-
8span of the erythrocyte, probably by a non enzymatic process. Patients with shortened
erythrocyte life-span due to hemolysis had markedly decreased levels of Hb A1c.
Koenig RJ 18 studied the increased levels of hemoglobins AIa+Ib and AIc in five
hospitalized diabetic patients to determine whether changes in diabetic control would
cause parallel changes in the levels of these hemoglobins.. They concluded that periodic
monitoring of hemoglobin AIc levels provided a useful way of documenting the degree of
control of glucose metabolism in diabetic patients and served as a means to assess the
relation of carbohydrate control to the development of sequelae.
Nathan DM 19 evaluated the clinical information value of the glycosylated
hemoglobin assay by comparing it with practitioners' estimates of glucose control over
the preceding 10 weeks in 216 diabetic patients. They concluded that the glycosylated
hemoglobin assay provided information about the degree of long-term glucose control
that is not otherwise obtainable in the usual clinical setting.
John WG et al 20 described a method for estimating hemoglobin A1c (HbA1c)
with a commercially available enzyme immunoassay system. The method was based on
micro titer plate technology, utilizing an antibody raised to hemoglobin, the epitope being
the Amadori product of glucose plus the first eight amino acids on the N-terminal end of
the beta chain of hemoglobin. Using this method, they obtained a reference interval of
2.8-4.9% (central 95%) for HbA1c in a non-diabetic population. The percentages of
hemoglobin that were HbA1c in diabetics (6.86% +/- 2.51%) were significantly greater
than in non-diabetics (3.46% +/- 0.52%).
9Liu et al 21 developed and validated a direct enzymatic HbA1c assay that utilized
a single channel on chemistry auto-analyzers without the need to run separate glycated
hemoglobin and total hemoglobin assays.  Diazyme Direct Enzymatic HbA1c Assay was
contended to be accurate and precise when compared to currently marketed medical
devices. The method was not adversely affected by interferences from common
hemoglobin variants in samples and considered to be cost effective, user-friendly and
adaptable to most general chemistry analyzers.
Fructosamine
Johnson RN 22 developed a novel manual method to measure serum
glycosylprotein as an index of diabetic control. The method relied on the ability of
ketoamines (fructosamines) to act as reducing agents in alkaline solution. The simple
colorimetric procedure permitted the assay of both a synthetic fructosamine and purified
albumin while severely limiting the contribution of interfering substances.
Armbruster DA8 reviewed five different methodologies to measure
fructosamine: Phenylhydrazine procedure, Furosine procedure, Affinity chromatography,
2-thiobarbituric acid colorimetric (TBA) procedure and Nitroblue tetrazolium
colorimetric (NBT) procedure. He stated that of the different methods, Affinity
chromatography and the NBT methods appeared to be the most practical means to assess
fructosamine quickly, economically and accurately.  As fructosamine reflected the
average blood sugar concentration over the past two to three weeks, it possessed a
clinical advantage of responding more quickly to changes in therapy than HbA1c, thereby
allowing improved glycemic control.
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Baker et al 23 used fructosamine (FA) assay as a screening test for occult diabetes
in groups of patients referred for oral glucose tolerance tests (OGTT)  and found the
specificity and sensitivity of fructosamine as a true diabetes predictor to be 88 and 91%
respectively. The fructosamine assay’s ability to distinguish between subjects with
impaired glucose tolerance and those with true diabetes was a definite advantage of the
test. The range of fructosamine, using the NBT assay was estimated to be 1.23 – 2.15
mmol/L in normal patients and 1.74 to 3.10 mmol/L in those diagnosed as diabetic.
Ludvigsen CW et al 24 found a very high degree of correlation (r = 0.8909)
between the hemoglobin Alc and fructosamine measurements in 269 proposed insured
whose blood glucose value was greater than 115 mg/dl. Using the fructosamine
frequency graph compiled over a six-day period with 5000 specimens they found the
upper limit (95th percentile) of normal to be 2.1 mmol/L.
Kouzuma T et al 25 developed an automated diazyme enzymatic assay for
glycated albumin in blood samples. The method involves use of albumin-specific
proteinase, ketoamine oxidase and serum albumin assay reagent. Glycated albumin
detected by this method correlated significantly with that detected by high-performance
liquid-chromatographic (HPLC) method. They concluded that the new enzymatic
method was simple, rapid, allowed multiple determinations and enabled quantitative
analysis of glycated albumin.
Wang et al 26 developed an enzymatic assay (The Diazyme GSP enzymatic
assay) for the in-vitro quantification of serum GSP. The assay demonstrated good
correlation with the Randox Fructosamine assay and was not affected by ascorbic acid,
11
bilirubin, hemoglobin, glucose, triglycerides, or uric acid at concentrations commonly
found in patient samples. They also developed applications of this assay for commonly
used automated chemistry analyzers.
Relationship between glycemic control and periodontal status
Sastrowijoto SH et al 27 evaluated the relationship between glycemic control and
the periodontal status in 22 type 1 diabetic adults. Patients were studied in two groups:
near normal metabolic control (HbA1c < 7.7%) and those with poor metabolic control
(HbA1c > 9.9%). No significant difference was found between the 2 test groups with
regard to periodontal condition and neither age nor the duration of diabetes mellitus
influenced the periodontal parameters.
Piché JE, Swan RH and Hallmon WW 28 presented two case reports to illustrate
how the glycosylated hemoglobin assay can be utilized by the periodontists. This assay
was presented as a relatively new test used in the diagnosis and monitoring of the diabetic
patients. Indication of the blood glucose level over an extended period of time (30 to 90
days) and no requirement for fasting prior to testing were considered as the main
advantages of this method over the traditional assays.
Sastrowijoto SH et al 29 evaluated the effect of improved metabolic control on
the clinical periodontal condition and the sub-gingival microflora of diseased and healthy
periodontal pockets in 6 ambulatory IDDM patients. HbAlc improved significantly with
intensive conventional insulin treatment. No effect could be demonstrated for PPD,
probing attachment level, BOP and the plaque index. Statistical analysis of improved
metabolic control on the sub-gingival microflora revealed that the percentage of
streptococci increased significantly only in diseased pockets. The results of the study
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indicated that improved metabolic control in IDDM patients had no potential impetus for
an improved clinical periodontal condition or on the sub-gingival bacterial flora.
Safkan-Seppälä B and Ainamo J 30 assessed the frequency and severity of
periodontal disease in 44 individuals with poorly controlled IDDM (PIDD, mean blood
glucose level of 11.8mmol/l and mean HbA1 level of 10.7%) and 27 subjects with
controlled IDDM (CIDD). Site-specific recordings were made for the plaque index,
gingival index, pocket depth, loss of attachment, bleeding after probing, gingival
recession and radiographic loss of alveolar bone. Under similar plaque conditions, adult
subjects with a long-term PIDD were found to have lost more approximal attachment and
bone than subjects with a CIDD.
de Pommereau V et al 31 evaluated the periodontal status of 85 French
adolescents with IDDM and 38 healthy controls in the same age group. Plaque control,
gingival inflammation and probing attachment level were evaluated. The inter-proximal
marginal bone level was assessed with bitewing radiographs taken on the first molars and
on areas presenting an attachment loss over 2 mm. Diabetic children had significantly
more gingival inflammation but no significant relation was found between gingival
condition and age, Tanner's index, HbAlc level or disease duration. None of the subjects
had sites with attachment loss > 3 mm or radiographic signs of periodontitis.
Seppälä B, Seppälä M and Ainamo J 32 investigated the progression of
periodontal disease in 26 subjects with poorly controlled IDDM (PIDD, mean blood
glucose of 12.5 mmol/l and a mean HbA1 of 10.1%)  and 12 subjects with controlled
IDDM (CIDD, mean blood glucose of 6.7 mmol/l and mean HbA1 of 9.2%). The plaque
index, gingival index, pocket depth, loss of attachment, bleeding after probing, gingival
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recession, and radiographic loss of alveolar bone were recorded. At baseline and 2 years
after the baseline examination, the PIDD subjects had similar plaque conditions, but had
more gingivitis and bleeding after probing when compared to  the CIDD subjects
Tervonen T and Oliver RC 33 evaluated the association between long-term
control of diabetes mellitus (DM) using the mean of HbAlc over the past 2-5 years and
periodontitis in 75 diabetics. Plaque, calculus (+/-), probing depth (pd) and attachment
loss (al) were recorded in a randomized half-mouth examination. An increase in the
prevalence, severity and extent of periodontitis with poorer control of diabetes was
observed. In a multiple regression analysis, calculus and long-term control of diabetes
were significant variables when pd > 4 mm. With calculus, the frequency of pd > 4 mm
increased from 6% in the well-controlled diabetics to 16% in the poorly-controlled ones.
They concluded that periodontitis in diabetics is associated with long-term metabolic
control and presence of calculus.
Unal T et al 34 investigated the relationship between the diseased state of the
periodontal tissues and serum fructosamine and the plasma glucose values in 71 non-
insulin dependent diabetes mellitus (NIDDM) patients and 60 non-diabetics. There was a
positive correlation between fructosamine and the degree of gingival bleeding (0.684),
however serum glucose levels had little or no correlation.
Pinson M et al 35 compared the periodontal status of a juvenile diabetic study
group with that of a non-diabetic controls. No statistically significant differences were
found between the groups for average attachment loss, probing depths, recession,
gingival index, plaque index, gingival fluid flow, bleeding on probing and there was no
correlation between the level of diabetic control (Glycated Hb) and clinical variables.
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However, the diabetic group had a higher average gingival index for most teeth and
higher or the same plaque index levels on all teeth relative to controls. Thus, a young
study population with type I diabetes mellitus was found to have significantly increased
severity of inflammatory gingival disease compared to controls of similar age.
Novaes AB Jr, Gutierrez FG and Novaes AB 36 evaluated the periodontal
disease progression of 30 Type 2diabetics and 30 non-diabetics. The diabetics were
divided into three subgroups: controlled, moderately controlled, and poorly controlled at
the end of the study. When comparing the two groups as a whole significant difference
was observed for AL. When diabetic patients were divided into subgroups, significant
differences were observed between the poorly controlled and the control groups for both
the PPD and periodontal attachment loss. The glycosylated hemoglobin test was found to
be more reliable than the fasting glucose analysis for the purpose.
Firatli E, Yilmaz O and Onan U37 examined the periodontal status of 77 IDDM
children and adolescents, 77 paired healthy, sex- and age-matched controls. Fasting blood
glucose, fructosamine and HbA1 values were determined. The mean PPD, CAL and the
parameters to assess diabetes mellitus were significantly higher for the diabetic group.
They found a positive correlation between the duration of diabetes and clinical
attachment loss and between the serum fructosamine and gingival index in the diabetic
group.
Taylor GW et al 38 tested the hypothesis that severe periodontitis in persons with
NIDDM increased the risk of poor glycemic control. Data from Gila River Indian
Community were analyzed for dentate subjects aged 18 to 67, diagnosed at baseline with
NIDDM baseline HbA1 < 9%; and who remained dentate during the 2-year follow-up.
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Medical and dental examinations were conducted at 2-year intervals. Severe periodontitis
was specified as baseline periodontal attachment loss of > 6 mm on at least one index
tooth; baseline radiographic bone loss of 50% or more on at least one tooth. Poor
glycemic control was specified as HbA > 9% at follow-up. Severe periodontitis at
baseline was associated with increased risk of poor glycemic control at follow-up. Other
statistically significant covariates were age, level of glycemic control, severe NIDDM,
duration of NIDDM and smoking: at baseline. These results supported severe
periodontitis as a risk factor for poor glycemic control.
Collin HL et al 39 investigated the periodontal status of 25 patients with
(NIDDM) (age range 58 to 76) and 40 non-diabetics (age range 59 to 77). Surfaces with
visible plaque and bleeding after probing, calculus, total AL and mean alveolar bone loss
were evaluated. Periodontal disease was considered advanced when mean alveolar bone
loss was over 50%, or 2 or more teeth had pockets > 6 mm. Patients with NIDDM had
significantly more advanced periodontitis than control subjects. The HbA1C level
deteriorated only in patients with advanced periodontitis, when compared to the situation
2 to 3 years earlier. Therefore, advanced periodontitis was considered to be associated
with the impairment of the metabolic control in patients with NIDDM.
Stewart JE et al 40 explored the effect of periodontal therapy on glycemic control
in type 2 diabetics. 72 type2 DM patients were studied, of whom 36 received therapy for
adult periodontitis and the rest without treatment formed the control group. During the
nine-month observation period, control group had 6.7% improvement when compared to
a 17.1% improvement in the treatment group, a statistically significant difference. They
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interpreted the data to suggest that periodontal therapy was associated with improved
glycemic control in persons with type 2 DM.
Alpagot T et al 41 investigated the associations between GCF elastase levels,
clinical measures of periodontal status and metabolic control of diabetes (HbA1c) in
type 1 and 2 diabetes. The results indicated that the elastase levels significantly correlated
with periodontal parameters in both the groups. However HbA1c levels did not correlate
with clinical measurements and GCF elastase. The results suggested that GCF elastase,
age and smoking are risk indicators for periodontitis in patients with diabetes mellitus,
and periodontal status is not associated with the duration and metabolic control of
diabetes.
Tsai C, Hayes C and Taylor GW 42 investigated the association between
glycemic control of type 2 diabetes mellitus and severe periodontal disease based on data
from 4343 persons from US adult population. Severe periodontal disease was defined as
2+ sites with 6+ mm loss of attachment and at least one site with probing pocket depth of
5+ mm. Individuals with poorly controlled diabetes (PCDM) had glycosylated
hemoglobin > 9% and those with better-controlled diabetes (BCDM) had glycosylated
hemoglobin ≤ 9%. The data indicated that the individuals with PCDM had a significantly
higher prevalence of severe periodontitis than those without Diabetes. For the BCDM
subjects, there was a tendency for a higher prevalence of severe periodontitis. These
results were considered to provide population-based evidence to support an association
between poorly controlled type 2 diabetes mellitus and severe periodontitis.
Syrjälä AM et al 43 analyzed the role of smoking and HbA1c level in attachment
loss (AL) and probing depths (PDs) among 64 IDDM patients. Data were obtained from
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patient records and by clinical examination. The outcome variables were the number of
sites with AL and PD of 5-9 mm. The results showed that the Relative risk (RR) among
the smokers was 4.15 for AL and 7.96 for PD. HbA1c was not related to AL or PD.
Among smokers with HbA1c > 8.5, RR for AL was 12.34. It was concluded that the poor
metabolic control together with smoking is extremely detrimental for attachment loss.
Jansson H et al 44 analyzed the association between medical characteristics and
severe periodontal disease in 191 subjects with type 2 diabetes (T2D). Based on
assessment of marginal bone height in panoramic radiographs, two subgroups were
identified: periodontally diseased and periodontally healthy group. Periodontally diseased
(20% of the subjects) individuals had higher HbA1c levels and higher prevalence of
cardiovascular complications. The best predictor for severe periodontal disease in
subjects with T2D was smoking followed by HbA1c levels.
Nesse W et al 10 discussed the shortcomings of the existing classification methods
for periodontitis that expressed the severity of the disease as non-continuous variables
(mild, moderate severe etc.). A new method that quantitatively expressed the severity of
periodontal disease using full mouth Clinical Attachment Level (CAL), recessions and
bleeding on probing (BOP) measurements. Attachment Loss Surface Area (ALSA) was
generated by transforming linear CAL measurements around a particular tooth into
surface area for that particular tooth.  Periodontal Epithelial Surface Area (PESA), the
surface area of pocket epithelium, was calculated from ALSA and Recession Surface
Area (RSA). Finally, the part of the PESA that is affected by BOP was termed the
Periodontal Inflamed Surface Area (PISA). This parameter was presented as the main
contributor to the systemic inflammatory burden posed by periodontitis and hence more
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relevant in assessing the relationship of periodontal disease with any systemic disorders.
Microsoft Excel spreadsheets that were specially designed to calculate all these
parameters from BOP, PPD and CAL measurements were presented along with details
about their online resources.
Nesse W et al 11 investigated whether a dose-response relationship existed
between the Periodontal Inflamed Surface Area (PISA) and HbA1c levels in 40 dentate
type 2 diabetics. PISA was calculated from full-mouth PPD and BOP measurements.
HbA1c levels were retrieved from patient’s medical files. Multiple linear regression
analysis were performed to analyze the association between these two variables The
results showed that the higher the PISA of type 2 diabetics, the higher their HbA1c
levels. On a group level, an increase of PISA by 333 mm2 was associated with a 1.0 %
increase of HbA1c, independent of the influence of other factors. They concluded that, on
a group level, there is a dose-response relationship between PISA and HbA1c in type 2
diabetics. This might be an indication of a causal relationship between type 2 diabetes
and periodontitis.
Hayashida H et al 45 analyzed the relationship between periodontal status and
glycosylated hemoglobin (HbA1c) in non-diabetic subjects. Periodontal status, HbA1c,
serum cholesterol, triglyceride, body mass index (BMI), and demographic variables were
assessed in 141 Japanese adults. The difference in the HbA1c level was evaluated among
subjects according to periodontal status. The mean HbA1c was significantly elevated
with periodontal deterioration. It was concluded that there was a significant relationship
between periodontal status and HbA1c levels in non-diabetics.
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Wolff RE, Wolff LF and Michalowicz BS 46 determined if HbA1c is elevated in
non-diabetic patients with periodontitis. HbA1c was assessed using a chair side test in 59
adults without diabetes but with periodontitis and 53 healthy controls. Unadjusted mean
HbA1c levels did not differ significantly between diabetic cases and controls. After
adjustments for age, gender, BMI, and current smoking, a higher proportion of cases
(27.3%) than controls (13.2%) had HbA1c values > 6%, although this difference was not
statistically significant (P >0.1). They concluded that periodontitis is associated with a
slight elevation in glycosylated hemoglobin.
Fernandes JK et al 47 assessed the prevalence of periodontal disease among a
sample of Gullah African Americans with diabetes. Diabetes control was assessed by
HbA1c and divided into; well controlled; <7%; moderately controlled; 7% to 8.5%; and
poorly controlled; >8.5%. Participants were categorized as healthy (no CAL or BOP),
early periodontitis (CAL >1 mm in at least two teeth), moderate periodontitis (three sites
with CAL > 4 mm and at least two sites with probing depth [PD] > 3 mm), or severe
periodontitis (CAL > 6 mm in at least two teeth and PD > 5 mm in at least one site).
They concluded that this population exhibited a higher prevalence of periodontal disease
as compared to African Americans. However, diabetes control was not associated with
periodontal disease in this population.
Awartani FA 48 investigated the association between glycemic control of type 2
diabetes mellitus (type 2 DM) and severity of periodontal disease (PD) in 126 Saudi
diabetic females. 74 patients formed Group I (better control with HbA1c <9%) while 52
formed Group II (poor control with HbA1c >9%). Plaque index, bleeding index, presence
of calculus, PPD, and CAL were recorded. The results revealed a significantly higher
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percentage of calculus, PD > 4 mm and loss of attachment level (3-4 mm) in the poorly
controlled diabetic patients, as compared to the better-controlled group.
Chen L et al 49 assessed the relationship of periodontal parameters with metabolic
levels and systemic inflammatory markers in 140 patients with type 2 diabetes and
periodontitis. Upon an analysis of covariance, subjects with an increased mean PD had
significantly higher levels of HbA1c.  After controlling for other factors, positive
correlations were found between mean PD and HbA1c. After adjustment for possible
confounders, the mean PD emerged as a significant predictor variable for elevated level
of HbA1c.
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MATERIALs AND METHODS
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The clearance from Institutional Ethical committee (Annexure 1) was obtained
prior to the study and the ethical principles as enumerated in the Helsinki declaration50
were meticulously followed throughout the course of the study.
I. Sample
Hundred successive patients, 60 with Type 2 diabetics (of more than 3 years
duration) from the Diabetology OPD, Government General Hospital, Chennai and 40
non-diabetic patients from the OPD of the Dept. of Periodontology, Tamil Nadu
Government Dental College and Hospital, Chennai, were included in this study. All the
patients met the following criteria.
Inclusion criteria
1. Generalized chronic periodontitis (clinically defined as CAL in
more than 30% of the sites examined)4 (Figure 1)
2. Age : 30-60 years
3. Voluntary participation and willingness to sign the informed consent
Exclusion criteria
1. Patients with anemia / hematological disorder 6
2. Patients with Protein Energy Malnutrition
3. Patients with other known systemic disorders
4. Patients requiring antibiotic premedication
5. Patients under steroids
6. Patients with a history of periodontal treatment in the past 6 months
7. Presence of any acute infection
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8. Pregnancy
II. Clinical parameters
After a thorough medical history and a signed Informed Consent from the patient
(Annexure 2 and 3) the following clinical parameters were evaluated.
1. Plaque Index (Pl I, Silness and Loe, 1964) 51
All teeth were examined at 4 sites each (disto-facial, facial, mesio-facial,
lingual/palatal) and were scored as follows
Score 0 – No plaque
Score 1 – Plaque not visible to the naked eye, detected by explorer
Score 2 – Thin to moderate accumulation of soft deposits within the
gingival pocket or on tooth, visible to the naked eye
Score 3 – Abundance of soft matter within gingival pocket or on tooth
surface and margin, interdental area stuffed with soft debris
Calculation: Plaque index for a tooth = Total score from 4 areas/ 4
Pl I = Total Plaque indices for all teeth / No. of teeth examined
Interpretation: 0 – Excellent oral hygiene
0.1 to 0.9 – Good oral hygiene
1.0 to 1.9 – Fair oral hygiene
2.0 to 3.0 - Poor oral hygiene
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2. Bleeding on Probing (BOP)
For every tooth starting from second molar, the probe was inserted gently into the
gingival sulcus at six sites per tooth (Mesiobuccal, Midbuccal, Distobuccal,
Mesiolingual, Midlingual, and Distolingual). The appearance of the bleeding at each site
indicated a positive score. The total number of bleeding sites per tooth was thus recorded
for every tooth except the third molar.
3. Probing Pocket Depth (PPD) (Figure 1)
Probing Pocket Depth was measured from the gingival margin to the base of the
pocket in millimeters using Williams Periodontal Probe. The probe was walked within
the gingival sulcus along the circumference of the tooth. Six measurements were made
per tooth (Mesiobuccal, Midbuccal, Distobuccal, Mesiolingual, Midlingual, and
Distolingual).
4. Clinical Attachment Level (CAL)
Clinical Attachment Level was measured from the Cemento – Enamel Junction
(CEJ) to the base of the pocket in millimeter using Williams Periodontal Probe (Figure
2). Three measurements were made on the buccal aspect and three on the lingual aspect
of each tooth – total of six sites per tooth (Mesiobuccal, Midbuccal, Distobuccal,
Mesiolingual, Midlingual and Distolingual).
4. Gingival Recession
When the gingival margin was located apical to the CEJ, recession was measured
at six sites per tooth (Mesiobuccal, Midbuccal, Distobuccal, Mesiolingual, Midlingual
and Distolingual).
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5. Attachment Loss Surface Area (ALSA), Periodontal Epithelial Surface Area (PESA)
and  Periodontal Inflamed Surface Area (PISA)10,11
These parameters were derived from Clinical attachment level (CAL), recession
and bleeding on probing (BOP) measurements. Excel Spreadsheets that are specially
designed for this purpose (Annexure 5) were downloaded and utilized.
To calculate the ALSA, the linear probing measurements, from the cemento–
enamel junction (CEJ) to the bottom of the pocket (i.e. CAL), around a particular tooth
are fed in the respective Excel cells. Based on the formula function already fed on the
excel sheet, these measurements were transformed into the ALSA for that particular
tooth. Summing up the individual ALSA scores for the teeth provided the total ALSA
score for the patient.
To calculate the PESA, the Recession Surface Area (RSA) was subtracted from
ALSA.  Since ALSA= PESA + RSA, it was deducted that ALSA – RSA = PESA. To
calculate the PESA there are three arithmetical possibilities, depending on the location of
the gingival margin (LGM): (Figure 3)
1. When LGM is below CEJ, RSA > 0 and PPD < CAL. Thus PESA < ALSA.
Therefore PESA = ALSA- RSA
2. When LGM is exactly at CEJ, PPD = CAL and RSA = 0.
Therefore PESA = ALSA
3. When LGM is above CEJ, PPD > CAL and hence PESA > ALSA.
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To calculate PISA, the inflamed part of the PESA, the following steps were
followed in the Excel spreadsheet available for this purpose.
1. When the CAL measurements at six sites per tooth are fed in the Excel spreadsheet, the
computer calculates the mean CAL for each particular tooth. This is automatically
transformed using the appropriate formula for the translation of linear CAL
measurements to the ALSA for that specific tooth
2. When the recession measurements at six sites per tooth are fed in appropriate cells, the
computer calculates the mean recession for each particular tooth. This is automatically
entered into the appropriate formula for the translation of linear recession measurements
to the RSA for that specific tooth
3. The computer generates the PESA of a particular tooth based on the above
measurements as PESA= ALSA – RSA.
4. The number of sites around the tooth that was affected by BOP is then entered into the
designated cells in the worksheet. The PISA for a particular tooth is automatically
generated by multiplying PESA by the number of sites with BOP. The sum of all
individual PISAs around individual teeth is calculated, amounting to the total PISA
within a patient’s mouth.
III. Lab investigations
1. Collection of blood sample
Prior to sample collection, skin preparation was done. Five ml of blood sample
(Figure 4a, 4b) was drawn from each patient using disposable hypodermic syringe with
23 gauge needle.  Blood was collected by venipuncture from antecubital fossa and
transported using standardized and aseptic technique (Figure 5).  The blood samples were
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analyzed for Glycated Hemoglobin (HbA1c) and Glycated Serum Protein (Fructosamine)
levels. Both the tests were done in Autoanalyzer. (Figure 6)
2. Plasma HbA1c Assay 52
HbA1c Assay was performed using Diazyme Direct Enzymatic HbA1c kit (Figure
7) in the Institute of Bio-Chemistry, GGH, Chennai-3. The kit consists of lysis buffer,
Reagents 1a, 1b, 2 and calibrator which need to be reconstituted before use.
Reagent Preparation -Diazyme HbA1c reagents R1a and R1b were mixed in a 7:3 ratio
and allowed to sit at 2-8ºC for 24 hours prior to use. It was mixed gently by inversion,
according to the instructions given by the Diazyme laboratories.
Specimen Collection and Handling - The venous whole blood samples were collected
with EDTA as anticoagulant. As per the instructions, these samples could be stored by
refrigeration and were used within 2 weeks of collection.
Assay Procedure - Whole Blood Bench Top Lysis Procedure
 250 μL of Lysis reagent was dispensed in an Eppendorf microfuge tube using
micropipette (Figure 8).
 Prior to testing, whole blood samples were mixed by gentle inversion at least 5
times to resuspend settled erythrocytes, because accuracy of the assay will be affected if
whole blood is not thoroughly mixed prior to testing.
 20 μL of fully resuspended whole blood sample was added to the lysis buffer
(Figure 9).  This was mixed gently with a suitable pipette without creating foam and
incubated at room temperature (25°C) for 10 min to completely lyse the red blood cells.
Complete lysis is observed when the mixture becomes a clear dark red solution without
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any particulate matter (Figure 10). The lysate, thus prepared was ready for use in the
Direct EnzymaticHbA1c assay and is stable up to 4 hours at room temperature.
 The lysate (20µL of whole blood + 250 µL of the lysis buffer) was then
transferred to the sample cup and along with the Reagents R1ab and R2 were run in the
autoanalyser. (Figure 11)
 The calibrators were treated exactly as patient samples and were used as per the
instructions on labeling.
Results - The HbA1c concentration was expressed directly as % HbA1c by use of a
suitable calibration curve in which the calibrators have values for each level in %HbA1c.
The values reported are aligned with the Diabetes Control and Clinical Trials (DCCT)
system. After addition of Reagent R1, sample and Reagent R2, the result of %HbA1c
were reported within 2 min.
3. Glycated Serum Protein Enzymatic Assay (Serum Fructosamine)52
GSP assay was done in autoanalyzer using Diazyme Glycated Serum Protein Enzymatic
kit (Figure 12) in the Institute of Bio-Chemistry, GGH, Chennai-3.
Reagent Preparation: The kit is supplied with Reagent 1, Reagent 2 and Calibrator.
R1 - As per the instructions, one vial Reagent 1 was reconstituted with 20 mL of distilled
water and mixed gently by inversion and then allowed to stand for 24 hours at 2-8°C
before use. The reconstituted R1 remains stable for 4 weeks at 2-8°C.
R2 - One vial Reagent 2 was reconstituted with 5 mL of distilled water, mixed gently by
inversion and then allowed to stand at room temperature for a minimum of 10 minutes
before use. The reconstituted R2 remains stable for 4 weeks at 2-8°C.
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Specimen Collection and Handling – The blood samples were centrifuged immediately
after collection and serum was separated from cells (Figure 13, 14) and stored in
Eppendorf tubes (Figure 15).
Assay Procedure - 20 µL of serum was dispensed into sample cup and run in
Autoanalyzer along with Reagent 1 and Reagent 2.
Results - Glycated Serum Protein results are printed out in μmol/L.
All the data collected from patients were entered in a standardized proforma(Annexure 4)
Statistical Analyses
The data for every patient was entered into Excel worksheet and was counter-
checked twice before subjecting for data analysis. The normality of the analyzed data was
tested with Kolmogorov-Smirnov test. Independent samples t test was used to evaluate if
any significant differences existed between the diabetic and non-diabetic groups based on
the Age, Plaque Index and ALSA. Differences between the groups for HbA1c,
Fructosamine and PISA were assessed for statistical significance with Mann-Whitney
test.
Pearson correlation (Bivariate) was used to analyze the strength of association
between the investigated variables.53,54 The correlation coefficient (r) was interpreted as
follows.
0.0 - 0.1 - Trivial,
0.1 - 0.3 - Low
0.3 - 0.5 - Moderate
0.5 - 0.7 - High
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0.7 - 0.9 - Very high
0.9 - 1 - Nearly perfect
Multiple linear regression analysis with backward elimination method was
performed to analyze the predictability of ALSA and PISA from the plasma HbA1c or
the serum Fructosamine values and other variables evaluated in the study. ALSA or PISA
were entered as dependent variables and HbA1c or Fructosamine values, gender, age,
duration of diabetes and Plaque Index as independent variables. The significance of the
contribution of the variables to the model was estimated and compared with the entry
criterion of 0.05 and removal criterion of 0.1 for the probability of F. When a potential
predictor met the removal criterion, it was removed from the regression model. The
model was then assessed for the remaining predictor variables and the process was
continued until no further predictors met the removal criterion. This resulted in the model
with minimum number of significant predictor variables.
The alpha level for all the analyses was set at 0.05 and all the statistical
procedures were performed in PASW statistics v.18.0.0 (SPSS Inc., 233 South Wacker
Drive, 11th Floor Chicago, IL 60606-6412. www.spss.com).
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Figure 2: Armamentarium for periodontal examination
Figure 1: Generalized Chronic Periodontitis
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AL- Attachment Level; ALSA- Attachment Loss Surface Area; CAL- Clinical Attachment  Level;
CEJ- Cemento Enamel Junction; LGM- Location of Gingival Margin;
PESA- Periodontal Epithelial Surface Area; PISA- Periodontal Inflamed Surface Area;
PPD- Probing Pocket Depth; RSA- Recession Surface Area;
Figure 3: Calculation of PESA
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Figure 5: Sample transportation kit
Figure 4b: Collected blood sampleFigure 4a: Collection of blood
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Figure 6: Auto analyzer
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Figure 7: HbA1c Kit
Figure 8: Micropipette 5-50µl
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Figure 9: 20 µl of whole blood in lysis buffer
Figure10: The lysed blood
Figure 11: Lysate transferred to sample cup
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Figure 15: Serum in Eppendorf
microfuge tube
Figure 12: Fructosamine Kit
Figure 14 : Centrifuged serum
Figure 13: Laboratory Centrifuge
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RESULTS
39
The summary statistics for the variables in both the diabetic and non-diabetic
group are presented in Table 1. Unpaired t test revealed no statistically significant
difference between these groups for age, Plaque index or ALSA. Similarly the inter-
group differences in HbA1c, Fructosamine and PISA also failed to reach statistical
significance. As expected, the levels of HbA1c and Fructosamine were significantly
higher in the diabetic group when compared to non-diabetic group (9.08 ± 1.6 vs. 5.68 ±
0.95 and 3.73 ± 0.97 vs. 2.33 ± 0.52 respectively, p<0.0001). Hence it could be
concluded that both the groups were well matched except for the diabetic status. A mean
HbA1c level of 9.08 ± 1.6 suggested that the glycemic control in the diabetic group was
poor.
The results of Pearson correlation test for the diabetic group (Table 2) revealed a
very high positive correlation between HbA1c and Fructosamine (0.862, p=0.000). While
ALSA correlated highly with both the glycemic markers, the correlations between PISA
with HbA1c and Fructosamine were high and moderate respectively. In the non-diabetic
group, no statistically significant correlation was evident between any of the glycemic
markers and ALSA or PISA (Table 3). However the Plasma HbA1c and Serum
fructosamine values exhibited a moderate correlation (r=0.436, p=0.005)
The multiple regression analysis ( backward method) revealed that the most
significant variables for predicting ALSA in the diabetic group were the glycemic control
as indicated by  HbA1c or fructosamine, plaque index and age ( Tables 4 and 5, Figure
16). The final model for PISA in diabetic group showed HbA1c or fructosamine level and
Plaque index to be the most significant predictor variables (Tables 6 and 7, Figure 17). In
the non-diabetic group, no predictor variables reached a statistically significant level for
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ALSA (Tables  8 and 9). For PISA in the non-diabetic group (Tables 10 and 11), Plaque
index emerged as the single most useful predictor, albeit explaining only 14.5% of the
variance in PISA.
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Table 1. Summary statistics for the Diabetic (n=60) and Non-diabetic (n=40) groups
D- Diabetic, ND – Non-diabetic, CI – Confidence Interval, Med – Median, SE – Standard Error,
SD – Standard Deviation, p – Probability value (two-tailed),
NS – Non-significant, ***- P<0.001
† - Unpaired t test, ‡ - Mann-Whitney U test
Parameter Group Mean 95% CI mean Med Range SE SD p
Age (years) DND
51.32
49.25
49.93 – 52.71
47.06 – 51.44
52
49
35 – 60
35 - 60
0.694
1.082
5.38
6.84
0.09
(NS)†
Duration
(years) D 8.26 7.31 – 9.21 7 3 - 20 0.475 3.68
Plaque Index DND
1.32
1.21
1.16 – 1.47
1.08 – 1.33
1.23
1.23
0.52 – 2.76
0.56 – 2.13
0.078
0.062
0.61
0.39
0.32
(NS) †
HbA1c DND
9.08
5.68
8.66 – 9.49
5.37 – 5.98
9.20
5.40
5-20 – 11.90
4.50 – 8.00
0.207
0.151
1.60
0.95
<0.0001
***‡
Fructosamine DND
3.73
2.33
3.48 – 3.98
2.16 – 2.50
3.77
2.17
1.39 – 5.40
1.75 – 4.59
0.126
0.083
0.979
0.529
<0.0001
***‡
ALSA DND
2071
2083
1941 – 2202
1892 - 2274
1970
1965
1008 – 3568
1189 - 4482
65.27
94.31
505.6
596.5
0.91
(NS) †
PISA DND
981
1172
844.7 – 1117
1634 - 1909
918.2
1116
219.2 - 1955
400.2 - 3276
68.08
83.13
527.7
525.8
0.35
(NS) ‡
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Table 2. Pearson correlation (Bivariate) for variables in the Diabetic group (n=60)
r - Pearson correlation coefficient, p – Probability value (two tailed)
*- p,0.05, ***- P<0.001
Age Gender Duration HbA1c FA Pl I PISA ALSA
Age r 1 -.101 .290
* .152 .177 .007 .083 .276*
p .443 .024 .247 .176 .956 .526 .033
Gender r -.101 1 -.027 -.057 -.021 -.092 -.177 -.116p .443 .838 .664 .874 .483 .175 .376
Duration r .290
* -.027 1 -.035 -.004 .084 .065 -.015
p .024 .838 .793 .976 .522 .624 .910
HbA1c r .152 -.057 -.035 1 .862
*** .265* .545*** .614***
p .247 .664 .793 .000 .041 .000 .000
FA r .177 -.021 -.004 .862
*** 1 .167 .445*** .513***
p .176 .874 .976 .000 .203 .000 .000
Pl I r .007 -.092 .084 .265
* .167 1 .598*** .529***
p .956 .483 .522 .041 .203 .000 .000
PISA r .083 -.177 .065 .545
*** .445*** .598*** 1 .679***
p .526 .175 .624 .000 .000 .000 .000
ALSA r .276
* -.116 -.015 .614*** .513*** .529*** .679*** 1
p .033 .376 .910 .000 .000 .000 .000
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Table 3. Pearson correlation (Bivariate) for variables in the Non-Diabetic group (n=40)
r - Pearson correlation coefficient, p – Probability value (two tailed)
*- p,0.05, **-p<0.01 ***- P<0.001
Age Gender Hba1c FA Pl I PISA ALSA
Age r 1 -.118 .247 .080 .113 -.198 -.171p .469 .125 .625 .489 .221 .292
Gender r -.118 1 .099 .060 .062 -.142 -.130p .469 .542 .712 .703 .384 .423
HbA1c r .247 .099 1 .436
** .371* .170 .053
p .125 .542 .005 .018 .293 .746
FA r .080 .060 .436
** 1 .554*** .292 .103
p .625 .712 .005 .000 .068 .527
Pl I r .113 .062 .371
* .554*** 1 .381* .169
p .489 .703 .018 .000 .015 .296
PISA r -.198 -.142 .170 .292 .381
* 1 .830***
p .221 .384 .293 .068 .015 .000
ALSA r -.171 -.130 .053 .103 .169 .830
*** 1
p .292 .423 .746 .527 .296 .000
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Table 4. Multiple regression (backward) for ALSA with HbA1c in diabetic group
Dependent variable – ALSA
Model 1 – Predictors: (Constant), Duration, Gender, HbA1c, Pl I, Age
Model 2 – Predictors: (Constant), Duration, HbA1c, Pl I, Age
Model 3 - Predictors: (Constant), HbA1c, Pl I, Age
Table 4A. Model Summary
Table 4B – Coefficients
Model R R Square R squarechange
Adjusted
R Square
SE of
Estimate
ANOVA
p value
1 .756 .571 .531 346.072 .000
2 .755 .570 -0.001 .539 343.3007 .000
3 .749 .561 -0.009 .538 343.827 .000
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B SE Beta
1
Constant -673.171 488.001 -1.379 .173
HbA1c 146.236 29.593 .465 4.942 .000
Pl I 338.949 77.195 .410 4.391 .000
Age 21.506 8.936 .229 2.407 .020
Gender -32.474 92.778 -.031 -.350 .728
Duration -13.814 12.899 -.101 -1.071 .289
2
Constant -712.742 470.923 -1.514 .136
HbA1c 146.419 29.352 .466 4.988 .000
Pl I 341.226 76.305 .413 4.472 .000
Age 21.802 8.825 .232 2.470 .017
Duration -13.852 12.796 -.101 -1.083 .284
3
Constant -697.679 471.439 -1.480 .145
HbA1c 149.928 29.217 .477 5.132 .000
Pl I 331.930 75.936 .402 4.371 .000
Age 18.895 8.420 .201 2.244 .029
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Table 5. Multiple regression (backward) for ALSA with Fructosamine in diabetic group
Dependent variable – ALSA
Model 1 – Predictors: (Constant), Duration, FA, Gender, Pl I, Age
Model 2 – Predictors: (Constant), Duration, FA, Pl I, Age
Model 3 - Predictors: (Constant), FA, Pl I, Age
Table 5A – Model Summary
Table 5B – Coefficients
Model R RSquare
R square
change
Adjusted R
Square
SE of
Estimate
ANOVA
p value
1 .722 .521 .477 365.63510 .000
2 .721 .519 -0.002 .484 363.02943 .000
3 .711 .506 -0.014 .479 364.82994 .000
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B Std. Error Beta
1
Constant -159.856 489.692 -.326 .745
FA 202.503 50.232 .392 4.031 .000
Pl I 387.299 79.668 .469 4.861 .000
Age 22.034 9.467 .235 2.327 .024
Gender -45.857 98.015 -.044 -.468 .642
Duration -16.754 13.583 -.122 -1.233 .223
2
Constant -213.719 472.574 -.452 .653
FA 202.189 49.869 .392 4.054 .000
Pl I 390.785 78.753 .473 4.962 .000
Age 22.477 9.353 .239 2.403 .020
Duration -16.827 13.486 -.123 -1.248 .217
3
Constant -178.494 474.070 -.377 .708
FA 206.826 49.977 .401 4.138 .000
Pl I 381.224 78.768 .461 4.840 .000
Age 18.989 8.969 .202 2.117 .039
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Table 6. Multiple regression (backward) for PISA with HbA1c in diabetic group
Dependent variable – PISA
Model 1 - Predictors: (Constant), Duration, Gender, HbA1c, Pl I, Age
Model 2 - Predictors: (Constant), Duration, Gender, HbA1c, Pl I
Model 3 - Predictors: (Constant), Gender, HbA1c, Pl I
Model 4 - Predictors: (Constant), HbA1c, Pl I
Table 6A – Model Summary
Model R R Square R squarechange
Adjusted R
Square
SE of
Estimate
ANOVA
p value
1 .729 .531 .488 377.428 .000
2 .729 .531 0.000 .497 373.990 .000
3 .728 .530 -0.001 .505 371.138 .000
4 .720 .518 -0.012 .501 372.505 .000
Table 6B – Coefficients
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B SE Beta
1
Constant -740.814 532.217 -1.392 .170
HbA1c 135.879 32.275 .414 4.210 .000
Pl I 409.528 84.189 .475 4.864 .000
Age -.469 9.746 -.005 -.048 .962
Gender -117.673 101.184 -.109 -1.163 .250
Duration 5.337 14.068 .037 .379 .706
2
Constant -761.362 315.077 -2.416 .019
HbA1c 135.603 31.469 .414 4.309 .000
Pl I 409.830 83.191 .475 4.926 .000
Gender -117.212 99.812 -.109 -1.174 .245
Duration 5.131 13.282 .036 .386 .701
3
Constant -715.856 290.002 -2.468 .017
HbA1c 134.874 31.173 .411 4.327 .000
Pl I 412.882 82.183 .479 5.024 .000
Gender -118.034 99.028 -.110 -1.192 .238
4
Constant -810.498 279.947 -2.895 .005
HbA1c 136.140 31.269 .415 4.354 .000
Pl I 420.736 82.221 .488 5.117 .000
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Table 7. Multiple regression (backward) for PISA with Fructosamine in diabetic group
Dependent variable – PISA
Model 1 - Predictors: (Constant), Duration, FA, Gender, Pl I, Age
Model 2 - Predictors: (Constant), Duration, FA, Gender, Pl I
Model 3 - Predictors: (Constant), FA, Gender, Pl I
Model 4 - Predictors: (Constant), FA, Pl I
Table 7A - Model Summary
Model R RSquare
R square
change
Adjusted
R Square
SE of
Estimate
ANOVA
p value
1 .704 .495 .448 391.700 .000
2 .704 .495 0.000 .458 388.123 .000
3 .703 .495 0.000 .468 384.769 .000
4 .693 .480 -0.015 .462 386.846 .000
Table 7B – Coefficients
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B Std. Error Beta
1
Constant -268.513 524.601 -.512 .611
FA 190.968 53.813 .355 3.549 .001
Pl I 453.677 85.347 .526 5.316 .000
Age -.081 10.142 -.001 -.008 .994
Gender -130.181 105.003 -.121 -1.240 .220
Duration 2.662 14.552 .019 .183 .856
2
Constant -272.170 251.491 -1.082 .284
FA 190.886 52.326 .355 3.648 .001
Pl I 453.717 84.416 .526 5.375 .000
Gender -130.097 103.521 -.121 -1.257 .214
Duration 2.627 13.761 .018 .191 .849
3
Constant -251.317 224.578 -1.119 .268
FA 190.702 51.865 .354 3.677 .001
Pl I 455.072 83.391 .528 5.457 .000
Gender -130.480 102.607 -.121 -1.272 .209
4
Constant -345.793 213.077 -1.623 .110
FA 191.077 52.144 .355 3.664 .001
Pl I 464.629 83.500 .539 5.564 .000
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Table 8. Multiple regression (backward) for ALSA with HbA1c in Non-diabetic group
Dependent Variable: ALSA
Model 1 - Predictors: (Constant), Gender, Pl I, Age, HbA1c
Model 2 - Predictors: (Constant), Gender, Pl I, Age
Model 3 - Predictors: (Constant), Pl I, Age
Model 4 - Predictors: (Constant), Age
Model 5 - Predictor: (constant)
Table 8A. Model Summary
Table 8B. Coefficients
Model R R Square R squarechange
Adjusted
R Square
SE of
Estimate
ANOVA
p value
1 .309 .096 -.008 598.819 .461
2 .305 .093 -0.003 .017 591.317 .314
3 .255 .065 -0.028 .015 592.117 .288
4 .171 .029 -0.036 .004 595.418 .292
5 .000 .000 -0.029 .000 596.491
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B SE Beta
1
Constant 2634.038 823.255 3.200 .003
HbA1c 35.809 111.205 .058 .322 .749
Pl I 276.938 260.417 .184 1.063 .295
Age -19.711 14.621 -.226 -1.348 .186
Gender -207.499 194.710 -.174 -1.066 .294
2
Constant 2743.147 740.892 3.702 .001
Pl I 306.332 240.838 .204 1.272 .212
Age -18.603 14.033 -.213 -1.326 .193
Gender -200.347 191.016 -.168 -1.049 .301
3
Constant 2560.078 721.011 3.551 .001
Pl I 287.032 240.459 .191 1.194 .240
Age -16.751 13.940 -.192 -1.202 .237
4 Constant 2815.405 692.392 4.066 .000Age -14.876 13.928 -.171 -1.068 .292
5 Constant 2082.783 94.314 22.084 .000
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Table 9. Multiple regression (backward) for ALSA with Fructosamine in Non-diabetic group
Table 9A. Model Summary
Table 9B. Coefficients
Dependent Variable: ALSA
Model 1 - Predictors: (Constant), Gender, FA, Age, Pl I
Model 2 - Predictors: (Constant), Gender, Age, Pl I
Model 3 - Predictors: (Constant), Age, Pl I
Model 4 - Predictors: (Constant), Age
Model 5 - Predictor: (constant)
Model R R Square R squarechange
Adjusted R
Square
SE of
Estimate
AVOVA
p value
1 .305 .093 -.010 599.563 .474
2 .305 .093 0.000 .017 591.318 .314
3 .255 .065 -0.028 .015 592.117 .288
4 .171 .029 -0.036 .004 595.418 .292
5 .000 .000 -0.029 .000 596.491
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B SE Beta
1
Constant 2705.342 806.224 3.356 .002
FA 28.123 217.721 .025 .129 .898
Pl I 285.696 291.816 .190 .979 .334
Age -18.649 14.233 -.214 -1.310 .199
Gender -201.197 193.791 -.169 -1.038 .306
2
Constant 2743.147 740.892 3.702 .001
Pl I 306.332 240.838 .204 1.272 .212
Age -18.603 14.033 -.213 -1.326 .193
Gender -200.347 191.016 -.168 -1.049 .301
3
Constant 2560.078 721.011 3.551 .001
Pl I 287.032 240.459 .191 1.194 .240
Age -16.751 13.940 -.192 -1.202 .237
4 Constant 2815.405 692.392 4.066 .000Age -14.876 13.928 -.171 -1.068 .292
5 Constant 2082.783 94.314 22.084 .000
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Table 10. Multiple regression (backward) for PISA with HbA1c in Non-diabetic group
Dependent Variable: PISA
Model 1 - Predictors: (Constant), Gender, Pl I, Age, HbA1c
Model 2 - Predictors: (Constant), Gender, Pl I, Age
Model 3 - Predictors: (Constant), Pl I, Age
Model 4 - Predictors: (Constant), Pl I
Table 10A. Model Summary
Table 10B. Coefficients
Model R R Square R squarechange
Adjusted R
Square
SE of
Estimate
ANOVA
p value
1 .505 .255 .170 478.879 .031
2 .493 .243 -0.012 .180 476.040 .017
3 .452 .204 -0.039 .161 481.530 .015
4 .381 .145 -0.059 .123 492.400 .015
Model
Unstandardized
Coefficients
Standardized
Coefficients t Sig.
B SE Beta
1
Constant 1346.112 658.361 2.045 .048
HbA1c 67.404 88.931 .123 .758 .454
Pl I 506.461 208.257 .382 2.432 .020
Age -22.772 11.693 -.296 -1.948 .060
Gender -223.095 155.711 -.212 -1.433 .161
2
Constant 1551.491 596.455 2.601 .013
Pl I 561.791 193.887 .424 2.898 .006
Age -20.686 11.297 -.269 -1.831 .075
Gender -209.633 153.778 -.200 -1.363 .181
3
Constant 1359.936 586.352 2.319 .026
Pl I 541.597 195.549 .409 2.770 .009
Age -18.748 11.336 -.244 -1.654 .107
4 Constant 480.754 252.943 1.901 .065Pl I 505.157 198.690 .381 2.542 .015
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Table 11. Multiple regression (backward) for PISA with Fructosamine in Non-diabetic group
Dependent Variable: PISA
Model 1 - Predictors: (Constant), Gender, FA, Age, Pl I
Model 2 - Predictors: (Constant), Gender, Age, Pl I
Model 3 - Predictors: (Constant), Age, Pl I
Model 4 - Predictors: (Constant), Pl I
Table 11A. Model Summary
Table 11B. Coefficients
Model Unstandardized Coefficients
Standardized
Coefficients t Sig.
B Std. Error Beta
1
Constant 1376.998 644.101 2.138 .040
FA 129.803 173.940 .131 .746 .460
Pl I 466.541 233.135 .352 2.001 .053
Age -20.898 11.371 -.272 -1.838 .075
Gender -213.554 154.822 -.203 -1.379 .177
2
Constant 1551.491 596.455 2.601 .013
Pl I 561.791 193.887 .424 2.898 .006
Age -20.686 11.297 -.269 -1.831 .075
Gender -209.633 153.778 -.200 -1.363 .181
3
Constant 1359.936 586.352 2.319 .026
Pl I 541.597 195.549 .409 2.770 .009
Age -18.748 11.336 -.244 -1.654 .107
4 Constant 480.754 252.943 1.901 .065Pl I 505.157 198.690 .381 2.542 .015
Model R R Square R squarechange
Adjusted R
Square
SE of
Estimate
ANOVA
p value
1 .505 .255 .170 478.997 .032
2 .493 .243 -0.012 .180 476.040 .017
3 .452 .204 -0.039 .161 481.530 .015
4 .381 .145 -0.059 .123 492.400 .015
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Figure 16: Percentage of variation in ALSA accounted by the Regression models
for the diabetic group.
Figure 17:  Percentage of variation in PISA accounted by the Regression models for
the diabetic group.
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DISCUSSION
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Diabetic patients are more susceptible to gingivitis and periodontitis than healthy
subjects.55,56,57,58 GCF glucose levels, periodontal vasculature, host response and collagen
metabolism are among the proposed mechanisms by which diabetes may affect the
periodontium 59. In hyperglycemic state, several proteins and matrix molecules undergo
a non-enzymatic glycosylation resulting in Advanced Glycation End Products (AGEs).
These AGEs play a central role in the classic complications of diabetes60 including the
progression of the periodontal disease.61 Hence it is critical to evaluate the level of
glycemic control in a diabetic patient, before initiating periodontal treatment.
From a periodontal point of view, random glucose and fasting blood glucose are
of limited value since they indicate the glucose concentration at the point of time.  The
most common of the available tests for monitoring the long and short term control of
glucose are the estimation of Glycated Hemoglobin or plasma HbA1c and Glycated
Albumin or serum fructosamine respectively.34 These are generated by a non-enzymatic
attachment of free carbonyl group of glucose through a Schiff base- Amadori
rearrangement at multiple sites on polypeptide chains of hemoglobin and albumin
respectively.8,62While HbA1c assay indicates the plasma glucose over 6-8 weeks (for the
average half-life of RBC is 60 days)28, Fructosamine reflects the glycemic conditions
during the preceding 1-3 weeks (half-life of albumin being 14-20 days).
Several studies have revealed correlation between plasma HbA1c and periodontal
disease severity.43,44,47,48,63 However, there is a scarcity of literature investigating the
association of the HbA1c with serum fructosamine status. Further, many studies
comparing HbA1c and Fructosamine levels with periodontal diseases severity, have
expressed periodontitis as a non-continuous variable such as mild, moderate, severe
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etc.10,11 or in terms of probing pocket depth and clinical attachment level. By definition,
these classifications do not quantify the amount of diseased or inflamed periodontal
tissue.10 Apparently only two studies are available that has utilized Attachment Loss
Surface Area (ALSA) or Periodontal Inflamed Surface Area (PISA) , the recently
introduced parameters that express the periodontal disease severity in truly quantitative
manner.10,11 The acute scarcity of literature for the comparative association of HbA1c
versus Fructosamine levels with periodontal disease severity, especially when the latter is
expressed in terms of ALSA and PISA, substantiates the need for and the appropriateness
of the current study.
Correlation between Glycemic control, ALSA and PISA
The results of bivariate correlation test (Pearson) in the present study showed that
Plasma HbA1c had a very high correlation with Serum Fructosamine levels in the
diabetic group ( r = 0.862, p=0.000, Table 2 ). Similar results have been reported by
Baker at al64 (r=0-82; p<0.001), Ludvigsen et al24 ( r = 0.890), Narbonne et al65( r= 0.88,
p,0.01) and Tahara66 (r = 0.747, p < 0.001) among diabetic patients. In contrast Ko et al67
found only a low level of correlation between them (r = 0.335, p<0.001) when adjusted
for age. In general, there appears to be a satisfactory level of correlation between HbA1c
and Fructosamine in diabetic patients thereby allowing the estimation of the former from
Fructosamine.
When the correlation between glycemic control and ALSA was assessed in the
diabetic patients in this study, plasma HbA1c had a marginally better correlation than
Fructosamine, though both fell under ‘high’ category ( r =0.614, p = 0.000 and r = 0.513,
p = 0.000 respectively).  Lack of any similar study in the literature has left no scope for
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the direct comparison of these results. Some of the earlier researches on the relation
between periodontal disease severity and glycemic control have found no association
between them.  In an investigation on 26 type I diabetic patients , Pinson et al35 found no
significant association between the level of control of diabetes (Glycated Hb) and
probing depths, clinical attachment levels or  recession. Similar results have been
reported by Alpagot et al 41 and Bridges et al.68
However the majority of later studies have identified a positive correlation
between the two. Negishi J et al 69 detected the high value of HbA1c to be significant
factor related to advanced periodontitis in diabetic patients.  Even among 12- to 18-year-
old diabetic children, glycemic control as indicated by HbA1c remained a highly
significant correlate of periodontitis. A positive correlation, has been reported between
mean PD and HbA1c in diabetic cases by Chen et al 49 (r = 0.2272; p = 0.009) and Lim et
al 70 ( r=0.26, p<0.05). In a study on 126 female type 2 diabetics, Awartani F 48 found a
significant association between the loss of attachment level (3-4 mm) and poor control of
diabetes. Slightly higher correlation values have been reported by Firatli et al 37 for Serum
fructosamine with PPD and CAL (0.23 and 0.32) than for Plasma HbA1c (0.13 and 0.27).
However no information regarding the statistical significance of this data has been
presented. Overall, there appears to be a positive correlation between plasma HbA1c and
PPD or CAL in diabetic patients. ALSA is a variable that quantifies the cumulative
periodontal destruction in an individual and is a derivation from either PPD or CAL.
Hence it is only logical that it shows a correlation with HbA1c or Fructosamine similar to
PPD and CAL.
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The evaluation of correlation between PISA and glycemic control in diabetic
cases of the present study showed results analogous to ALSA, with HbA1c exhibiting a
better correlation. In terms of strength of the correlation, that of HbA1c with PISA was
high (r = 0.545, p = 0.000) and that of Fructosamine was ‘moderate’ (r = 0.445, p =
0.000).  PISA is a continuous variable that quantifies the extent of active periodontal
disease in an individual and hence systemic burden resulting from it. It is a product of
periodontal pocket area (a derivation from PPD) and the number of sites with bleeding on
probing. PPD has been shown to correlate positively with HbA1c in several studies.
Similarly bleeding on probing has also been found to be significantly associated with
glycemic control. The vascular changes in diabetes mellitus result in increased gingival
bleeding with the thickening of the basement membrane of the small vessels in the
gingival tissues being one of them.71,72 Lu et al63 found that  the mean Gingival Index
values for Type 2 diabetics with HbA1c > 10% were more than those with HbA1c < 10
%.  Serum fructosamine showed positive correlation with gingival index in both insulin-
dependent diabetic children and adolescents (r=0.68)73 and NIDDM patients (r =
0.684).34 Gingival collagenase activity has been shown to reach a maximum in 15-22
days after the development of gingivitis in diabetes. The span of fructosamine turnover
approximately coinciding with this activation period of gingival collagenase has been put
forward as the possible explanation of high correlation between serum fructosamine and
gingival bleeding.34 Given that PISA represents the pocket area with bleeding on probing
and that glycemic control shows good correlation with both PPD and BOP, the
correlation between HbA1c and fructosamine with PISA appears plausible.
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The results of non-diabetic controls showed a moderate correlation between
HbA1c and fructosamine levels (r= 0.436, p=0.005, Table 3), but lesser than that
observed for the diabetic group. This is in agreement with Misciagna et al 74, who have
reported a similar correlation between fructosamine and HbA1c (r= 0.41) in non-
diabetics. However, Narbonne H et al 65 found a good correlation (r = 0.88) only in
diabetic patients and not in control subjects (r = 0.01). As for the relation between
glycemic control and periodontal disease severity in the current sample, HbA1c or serum
Fructosamine levels showed a positive, but trivial, correlation with ALSA (r=0.053,
p=0.746 and r= 0.103,p=0.527 respectively). Both exhibited a mild correlation
(r=0.170, p=0.293 and r= 0.292,p=0.068 respectively) with PISA. Similar are the
findings of Hayashida et al 45 and Wolf et al 46 who found a significant relationship
between periodontal status and Plasma HbA1c levels in non-diabetic individuals.
Though HbA1c is considered as the “gold standard” for assessing glycemic
control, a  number of hemoglobinopathies cause false results in HbA1c determinations,
thus presenting a unique challenge to clinical practitioners. Several conditions may affect
HbA1c determination include decreased lifespan of red blood cells secondary to massive
bleeding, hemolytic anemia, chronic disease or pregnancy induced anemia. In addition,
other causes affecting HbA1c determination are uremia, opiate addiction, chronic alcohol
abuse, high dose aspirin, hyperbilirubinemia, vitamin C excess, vitamin E excess, iron
deficiency anemia or hypertriglyceridemia.6 In such cases, serum fructosamine provides
an alternative glycemic marker.  Fructosamine responds much sooner to changes in
glycemic control level, enabling us to evaluate the treatment regimen sooner, since it
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represents the time averaged plasma glucose level over 2–4 weeks 66. The other added
advantages include low cost and simple laboratory procedure 9.
Considering, a satisfactory level of correlation between these glycemic markers
and either of them with periodontal disease status, Fructosamine appears a justifiable
alternative for HbA1c in generalized chronic periodontitis patients with Type 2 diabetes
mellitus.
Prediction models for ALSA and PISA
The current study explored the predictability of ALSA and PISA from the
glycemic control (HbA1c or Fructosamine), duration of diabetes (not applicable in the
non-diabetics), Age, gender and Plaque index of the individual using multiple linear
regression analysis. ALSA or PISA was entered as the independent variable and Age,
Gender, HbA1c or Fructosamine, duration of diabetes and Plaque index were introduced
as the predictor variables. A backward method was used for the selection of the predictor
variables in which all the predictor variables are entered into the model. The weakest
predictor variable is removed from the model and the regression re-calculated. If this
does not significantly weaken the model, the predictor variable is deleted. This is
repeated until the final model which contains only the useful predictors is produced.75
In the present study, the regression analysis for ALSA using HbA1c in diabetic
group resulted in a final model containing Plaque index, HbA1c and Age as the
significant predictor variables accounting for 53.8 % of the variance in ALSA (Table 4).
Gender and duration of diabetes had contributed only 1% (r2 change of 0.010) to the
variance in ALSA and hence were eliminated from the final model. HbA1c appeared to
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be the most influential variable followed closely by   Plaque Index and then by Age in
decreasing order.  A similar model resulted when the regression analysis was run with
fructosamine in place of HbA1c with Plaque Index, Fructosamine and Age being
significant predictors in the decreasing order of relative influence on ALSA (Table 5).
However this model accounted for a slightly lesser amount of variance in ALSA (47.9%)
than HbA1c final model. Of three variables, Plaque index had the highest impact on
ALSA followed closely by serum fructosamine level.
In general, the glycemic control, the local environment (as represented by plaque
index in this study) and age appeared to be the important variables on predicting the
ALSA, a measure of the cumulative periodontal destruction in an individual. This
supports Novak and Novak’s enlisting of tobacco smoking, diabetes, pathogenic bacteria
and microbial tooth deposits as the main risk factors for periodontal disease.4 Genetic
factors, age, gender, socioeconomic status and stress have been put forward as the
background characteristics that affect the periodontal disease status.4 Smoking has clearly
been identified as the best predictor of attachment loss in diabetic patients.43,44 While few
reports have failed to observe a significant association between glycemic control and
periodontal disease,27,31,35,76,77,78,79 and many have reported a significant relationship
between the two.32, 47,70,80-82 The role of plaque and calculus in having a pathogenic effect
on the progression of periodontal disease has also been well documented.42,83-86
Increased prevalence and severity of periodontal disease has been reported in old age,
with the attachment loss and bone loss  in these individuals seen as a cumulative effect
of the result of prolonged exposure to other risk factors over a person's life.87,88 The final
model of regression analysis for ALSA in the study corroborates the findings on the
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causative or contributory role of glycemic control in diabetes along with plaque and age
in the cumulative effect of periodontal disease in an individual.
The negligible effect of duration of diabetes on periodontal disease severity are in
agreement with Bridges et al 68, Rylander et al 76, Ervasti et al 80,  who did not find
relationship between the two.  On the contrary, Firatli E 37 and Lu HK 63 have shown
positive correlation between duration of diabetes and CAL.  Similarly, the negligible
contributory influence of gender on the periodontal disease severity is also in contrast to
certain reports of increased loss of attachment in males.4,84 As smoking was as an
exclusion criteria for the samples in the study, its contributory effect could not be
evaluated. This factor could probably be a major contributor towards the  nearly 50% of
the variance in ALSA that remains unexplained in the final prediction models of the
study.
In our study, the HbA1c and Fructosamine based regression models for PISA
showed these measures along with Plaque index accounted 50.1% and 46.2% of the
variance in PISA respectively (Table 6, Table 7). Akin to the condition for ALSA, gender
and duration of diabetes had either a very meager or no effect on the variance of PISA.
However, unlike for ALSA, age did not show any causal influence towards the variance
in PISA. Age related recession has been the primary modus through which age
contributes to periodontal disease severity measured in terms of CAL. Recession is not a
consideration in the calculation of PISA and hence the absence of age as in the final
predictive model for PISA is not surprising.  PISA, by definition, is the pocket surface
that bleeds on probing indicating the sites with active disease. The role of microbial
plaque in causing gingivitis is well established, with bleeding on probing being the
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cardinal sign. The vascular changes in diabetes mellitus resulting in increased gingival
bleeding have also been well documented.72,89 Many studies have reported a higher
gingival index in diabetics as compared to controls.34,63,73 Hence, the appearance of
Plaque index and HbA1c / fructosamine level as the most important variables for
predicting PISA appears reasonable. Nesse et al 11 assessed a dose–response relationship
between PISA and HbA1c levels in forty type 2 diabetics. After controlling for factors
that might influence PISA or HbA1c levels, the higher the PISA of type 2 diabetics was,
the higher their HbA1c levels were. On a group level, an increase of PISA with 333 mm2
was associated with a 1.0 percentage point increase of HbA1c, independent of the
influence of other factors, thus suggesting a causal relationship between periodontitis and
diabetes mellitus.
In the non-diabetic group with generalized chronic periodontitis, the backward
multiple regression analysis could not find any statistically significant model for
predicting ALSA from HbA1c or Fructosamine (Table 8, Table 9). For the prediction
model of PISA both HbA1c and Fructosamine were eliminated as the first variable.
Plaque index emerged as the single most important predictor accounting for 12.3% of the
variance in PISA with glycemic status, gender and age together contributing to 11% of
the variance (Table 10, Table 11). The effect of microbial plaque resulting in gingivitis
and thereby gingival bleeding could be the possible explanation for this result.
One main methodological advantage of this study is the use of enzymatic assay
method to estimate the levels of plasma HbA1c and serum Fructosamine. Many studies in
the periodontal literature, have utilized High Performance Liquid chromatographic
method for the estimation of glycosylated hemoglobin.37, 45, 70, 90 A chair side method for
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determination of HbA1c (A1c Now+, Bayer Health Care) has been reported by Wolff et
al.46 Overall, a majority of the laboratory methods require dual channel testing, i.e.
separate tests are required for glycated hemoglobin (GHb) and for total hemoglobin
(THb). The final %HbA1c value is expressed as a ratio of the specific GHb in relation to
the THb found in the whole blood sample. However, the Direct Enzymatic HbA1c Assay
used in the present study, is a single channel test and reports % HbA1c values directly,
without the need for a separate Total Hb test or a calculation step. It has all the
advantages of both the HPLC and immunoassays methods in the areas of accuracy,
specificity, applicability to chemistry analyzers and yet is cost effective, simpler and has
less interference.  Moreover, enzymatic HbA1c assays are neither interfered by chemical
or genetically modified hemoglobin variants nor reports false results regardless of the
patient’s hemoglobin variant types and are therefore highly reliable.
Similar to HbA1c, the serum Fructosamine was also evaluated using Diazyme
Enzymatic Fructosamine assay.26 Unal et al34 and Firatli et al73 have used Nitroblue
Tetrazolium (NBT) colorimetric procedure to determine Fructosamine levels. With a
mean intra assay <2% and mean inter-assay CV of <3%,52 the enzymatic assay used in
this study has definite advantages of improved specificity and reliability over the
conventional NBT-based method.
The majority of the studies and most of the indices quantifying the severity of
periodontal disease use limited number of sites or teeth in the patients mouth ( most often
the Ramjford teeth -11,16, 24, 31, 36, 44) 63 thereby intrinsically introducing a possibility
of under or overestimation of the condition. Assessing at six sites per tooth and inclusion
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of all the teeth (except third molars), as done in the current study is likely to be more
accurate than those from few representative teeth.
Limitations and future scope
A few limitations of the study require special consideration, the most significant
being a relatively low sample size of 60 type 2 diabetes and 40 non-diabetics.  Hence the
results of the study cannot be generalized without reservations.  In addition, the mean
plasma HbA1c and Serum Fructosamine values of the diabetic group in this study
indicated a poor glycemic control. Therefore the models derived here may be better
representative of the association between glycemic control and periodontal disease
severity in poorly controlled diabetes mellitus. The applicability of these models in
patients with good glycemic control requires further scrutiny.
The effect of smoking and other variables like socioeconomic status and stress
have not been evaluated in the current study. Including them could have resulted in a
more comprehensive prediction model for ALSA and PISA.
PISA, as a periodontal parameter, has some inherent disadvantages.  PISA
quantifies the amount of inflamed periodontal tissue in two dimensions, whereas
periodontitis is a three dimensional inflammatory process, i.e., it extends into the
connective tissue around the root.  However, the same is applicable even for conventional
parameters like CAL, BOP, PPD etc. Hence it can be contended that , though not precise,
ALSA and PISA  quantifies the amount of affected periodontal tissue more accurately
than any classification currently used (face validity).
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The formulas used to derive ALSA and PISA in the excel spreadsheets devised by
Nesse et al10 have used means for root lengths and root surface areas derived from their
population. Thus individual and population variations in these variables have been
overlooked when calculating ALSA and PISA.  This could be addressed partially by
utilizing the mean root surface areas and root lengths in our population.
Due to high variation in the development and eruption, the third molars have not
been included in the calculation of ALSA and PISA. Though this would impart greater
convenience and consistency in the clinical readings, it could have lead to slight
underestimation of ALSA and PISA in whom they are erupted and functional.
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Summary & Conclusions
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The association between the two markers of Glycemic control, Plasma HbA1c and Serum
Fructosamine levels and periodontal disease severity expressed in terms of Attachment
Loss Surface Area (ALSA) and Periodontal Inflamed Surface Area (PISA) were
evaluated in 60 type 2 diabetics and 40 non-diabetic patients with generalized chronic
periodontitis.
Within the limitations the study, the following conclusions were drawn
1. Plasma HbA1c and Serum Fructosamine exhibited a high correlation in generalized
chronic periodontitis patients with in type 2 diabetes mellitus and a moderate level
of correlation in periodontitis patients without diabetes.
2. Both these markers exhibited a marginally better correlation with ALSA than with
PISA in type 2 diabetics.
3. Albeit in the comparable range, Plasma Hba1c showed slightly higher correlation
than Serum  Fructosamine, both with ALSA and PISA in type 2 diabetics
4. No significant correlation was observed in non-diabetics, for either of these markers
of glycemic control with ALSA or PISA.
5. Glycemic control as indicated by Plasma HbA1c or Serum Fructosamine, Plaque
index and Age appeared to be the important predictor variables for ALSA
accounting for nearly half of its variance.
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6. HbA1c and Fructosamine based regression models for PISA in diabetic patients
showed that these measures along with plaque index accounted for 50.1% and
46.2% of the variance in PISA respectively.
7. None of the variables evaluated in the study (HbA1c/ Fructosamine, Plaque index,
Age, Gender and Duration of diabetes) were significantly predictive of ALSA in the
non-diabetic group. The most significant variable for predicting PISA in this group
was Plaque index, although it accounted only to 10 % of variance in PISA.
Considering the high association between Plasma HbA1c and Serum
Fructosamine and a comparable level of association of ALSA and PISA with either of
them, it seems justified to use Fructosamine as a valid alternative for HbA1c in the
evaluation of glycemic control in generalized chronic periodontitis patients with type 2
diabetes mellitus. Further studies incorporating a larger sample size and including further
variables are required before drawing more definitive conclusions and predictive models
for periodontal disease.
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ANNEXURES

Annexure 2
INFORMED CONSENT FORM
AN EVALUATION OF THE RELATIONSHIP BETWEEN PERIODONTAL DISEASE STATUS
AND GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
Name: O.P.No:
Address: Code No:
Age / Sex:
Tel. no:
I, ___________________________________________________, aged ______ years, am exercising my
free power of choice and hereby voluntarily consent to be included as a participant in this study.
I agree to the following:
 I have been informed to my satisfaction about the purpose of the study and study procedures
including the investigations to monitor and safeguard my body function.
 I understand that the lab investigations will require the procurement of my blood in required
amount.
 I agree to cooperate fully and to inform my doctor immediately if I suffer any unusual symptom.
 I have informed the doctor about all medications I have taken in the recent past and those I am
currently taking.
 I hereby give permission to use my medical records for research purpose. I am told that the
investigating doctor and institution will keep my identity confidential.
Name of the patient Signature / Thumb impression
Name of the investigator Signature Date
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Annexure 4
DEPARTMENT OF PERIODONTICS
TAMILNADU GOVERNMENT DENTAL COLLEGE AND HOSPITAL,
CHENNAI 600003
------------------------------------------------------------------------------------------------
An Evaluation of the Relationship between Periodontal Disease Status and Glycemic
Control in Patients with Type II Diabetes Mellitus
PROFORMA
Name : Age / Sex:
O.P. No : Code No :
Occupation : Income :
Address and Contact No.:
Chief Complaints
Pain / Shaky teeth / Bleeding gums / Swollen Gums / Receding Gums / Pus Discharge /
Increase in Spacing between teeth / Stains / Others.
Duration:
Medical history
1. Diabetes Mellitus.
a. Duration : __________ years
b. Recent change of anti-diabetic drug ( past 4 months)
c. Recent history of hospitalization with diabetic complication
2. Pregnancy / Lactation
3. Bleeding disorders or any other hematological disorder
4. Known systemic disease
5. Under steroids
Dental history
Periodontal treatment in the past 6 months
Clinical Examination
PLAQUE INDEX – SILNESS & LOE (1964)
BLEEDING ON PROBING
CLINICAL ATTACHMENT LEVEL and PROBING POCKET DEPTH (in mm)
17 16 15 14 13 12 11 21 22 23 24 25 26 27
47 46 45 44 43 42 41 31 32 33 34 35 36 37
Buccal
17 16 15 14 13 12 11 21 22 23 24 25 26 27
Palatal / Lingual
47 46 45 44 43 42 41 31 32 33 34 35 36 37
Buccal
Buccal
CAL
PPD
17 16 15 14 13 12 11 21 22 23 24 25 26 27
PPD
CAL
Palatal / Lingual
CAL
PPD
47 46 45 44 43 42 41 31 32 33 34 35 36 37
PPD
CAL
Buccal
DIAGNOSIS:
Sample Details
Date: Time:
INVESTIGATION:
Plasma HbA1c -
Serum Fructosamine -
INFERENCE:
Signature of the P.G student
Annexure 5
Excel spread sheet for calculation of ALSA and PISA
Annexure 6
Master chart
Diabetic group
Sl.No Age Gender Duration HbA1c FA Pl I ALSA PISA
1. 50 F 8 7.9 3.36 0.6 1618.99 375.87
2. 54 M 12 8.2 3.74 1.2 1846.16 488.68
3. 52 F 6 10.7 4.02 1.8 2311.18 619.59
4. 42 M 10 11.9 4.56 2.3 2558.84 1727.98
5. 42 F 4 10.1 3.65 0.7 1877.17 445.61
6. 48 F 5 8.9 3.6 0.78 1474.38 905.31
7. 55 F 8 9.6 4.37 0.65 1678.78 1091.23
8. 60 F 15 6.6 2.3 1.6 1648.29 285.24
9. 47 F 6 6.8 3.55 0.67 1601 366.06
10. 56 F 6 7.1 2 1.2 1848.74 395.81
11. 51 M 15 8.5 2.57 1.4 1739.01 460.5
12. 53 M 4 10.1 4.46 2.6 2627.46 1887.02
13. 35 F 7 6.4 2.45 1.32 1695.84 475.35
14. 55 F 15 8.7 2.95 2.32 1969.83 979.51
15. 59 F 9 10.2 4.88 1.3 2200.32 624.05
16. 48 F 7 9.2 3.83 2.25 1605.27 931.1
17. 54 M 5 10.6 4.69 2.04 2606.77 1431.95
18. 53 F 10 11.6 4.93 1.78 3031.1 1843.41
19. 55 M 8 11 4.12 1.45 2894.73 1752.2
20. 54 F 15 9.2 4 0.6 1329.93 312.95
21. 51 M 7 10.6 3.57 1.86 2494.8 1722.94
22. 50 F 4 11.2 5.08 1.32 2359.08 1698.88
23. 44 M 16 7 3.01 1.24 1111.92 479.38
24. 59 F 20 9.3 4.59 1.98 2994.08 1954.79
25. 56 F 7 8.7 2.69 2.45 3082.41 1766.35
26. 57 M 10 9.1 2.8 1.33 2089.22 1202.52
27. 58 M 8 10.2 4.9 2.76 3568.44 1385.2
28. 58 M 5 5.6 2.13 1.04 1007.86 219.15
29. 40 F 5 10.1 4.28 2.23 2358.23 1839.25
30. 38 F 7 7.9 3.25 2.34 1994.66 1046.96
31. 46 F 6 8.4 3.11 1.02 1467.22 424.33
32. 49 M 7 7.8 1.7 0.97 1681.76 337.9
33. 45 F 5 8.3 3.46 1.76 2383.8 896.79
34. 49 F 8 6.1 2.36 1.23 1863.65 348.17
35. 50 F 9 10.4 3.54 0.78 2001.12 1247.62
36. 56 F 5 9.1 4.21 0.67 2224.07 449.04
37. 58 F 4 8.1 3.52 0.78 1714.19 344.39
Non-diabetic group
Sl.No Age Gender HbA1c FA Pl I ALSA PISA
1. 48 0 5.2 1.98 0.97 1713.33 799.91
2. 35 1 5.1 2.12 1.23 2734.56 1598.29
3. 42 1 7.3 2.2 1.04 2203.99 1236.6
4. 59 0 4.8 2.16 1.08 1743.23 671.35
5. 58 0 5.8 2.22 1.3 2584.66 870.28
6. 46 0 5.2 1.94 1.08 2724.49 1680.42
7. 52 0 5.6 2.43 0.65 2469.41 1226.98
8. 44 1 6 2.19 1.02 2267.56 757.28
9. 40 0 5.2 2.16 1.12 2416.96 1207.56
10. 37 1 6.1 2.08 1.45 1559.39 943.72
11. 60 1 6.6 2.37 1.2 1401.57 837.53
12. 45 1 4.7 1.75 0.65 1778.13 884.74
38. 51 M 4 9.5 4.04 1.04 2269.79 473.76
39. 51 M 8 10.5 5.14 0.7 2308.14 549.72
40. 45 M 6 6.9 2.94 1.06 1692.95 1211.11
41. 53 M 8 10.8 4.95 1.65 1919.34 1330.8
42. 50 M 12 8.4 3.56 0.65 1523.18 888.18
43. 57 M 10 10.4 4.55 1.28 2316.48 1118.8
44. 52 F 6 8.3 3.03 0.56 1796.92 399.98
45. 52 M 12 10.8 5.33 0.98 1857.7 1201.04
46. 57 F 10 8.2 3.8 1.23 1689.32 1142.08
47. 54 F 6 10.8 5.08 0.67 1937.61 637.94
48. 56 F 13 11 4.73 2.56 2305.61 1784.1
49. 58 F 15 10.9 4.66 1.02 2880.16 1640.78
50. 55 M 11 9.2 4.34 1.23 2696.84 1521.28
51. 48 F 6 8 2.63 0.52 1945.59 583.98
52. 47 F 5 10.5 4.92 1.78 2065.32 1325.52
53. 50 F 5 11.6 5.4 0.98 2391.23 828.5
54. 52 M 5 9.6 4.1 0.87 2234.69 1545.96
55. 48 F 8 10.4 4.57 0.68 2024.08 700.21
56. 49 F 10 8 3.24 0.75 1969.43 905.33
57. 56 M 3 9.6 3.89 1.45 2706.04 1207.01
58. 54 F 12 7.3 2.75 0.67 1897.7 482.49
59. 48 M 7 5.2 1.39 0.89 1592.06 1126.28
60. 49 F 6 7.7 2.78 1.65 1704.06 1489.21
13. 56 1 4.9 2.02 1.23 1799.91 400.21
14. 48 0 4.5 1.95 0.56 1188.93 426.15
15. 49 0 4.6 2.34 0.78 1405.25 471.62
16. 52 0 7.6 1.75 0.56 1957.02 1298.7
17. 56 1 7.4 2.11 1.23 1882.84 752.97
18. 53 1 4.9 1.8 1.21 2180.24 1136.74
19. 47 1 4.7 2.1 1.02 1644.84 619.07
20. 52 0 5 1.85 0.76 2651.32 1460.13
21. 60 0 5.5 2.33 1.32 1843.78 1133.28
22. 52 1 5.4 1.75 0.67 2337.58 482.28
23. 38 1 5 2.1 0.78 1223.5 438.26
24. 56 1 5.1 2.44 1.43 1972.56 1168.58
25. 47 1 5.3 2.6 1.56 2001.12 1293.05
26. 46 1 4.5 2 1.23 1527.37 459.99
27. 54 1 8 3.1 1.45 1782.2 1031.47
28. 49 0 5.9 2.12 1.76 2278.17 1260.92
29. 50 1 5.3 2.09 1.44 2391.23 1514.29
30. 57 1 7.5 3.17 2.13 1607.68 1162.86
31. 39 1 5 2.34 0.87 2314.83 1198.18
32. 46 0 5.6 2.43 1.56 4482.24 3276.44
33. 55 1 5.5 2.54 0.65 2309.95 824.24
34. 60 1 5.8 2.13 1.44 1723.81 1112.71
35. 48 1 7 4.59 1.65 2655.99 1966.29
36. 51 0 5.7 2.54 1.87 1741.68 1251
37. 49 0 5.4 3.44 1.54 1643.17 979.89
38. 40 1 5.4 2.64 1.76 3085.2 1858.05
39. 54 0 7.6 2.93 1.87 2358.23 892.83
40. 40 0 5.5 2.43 1.33 1723.42 1120.17
